Italia Grenga

List of Publications by Year
in descending order

23	1,454	471061	839053
papers	citations	17	18
		h-index	g-index

23	23	23	2527
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors. Clinical Cancer Research, 2018, 24, 1287-1295.	3.2	304
2	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncology, The, 2017, 18, 587-598.	5.1	261
3	Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. Cancer Immunology Research, 2015, 3, 1248-1256.	1.6	118
4	The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. Oncotarget, 2016, 7, 37762-37772.	0.8	96
5	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer. JAMA Oncology, 2015, 1, 1087.	3.4	80
6	Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. , 2017, 5, 20.		78
7	Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. International Journal of Colorectal Disease, 2011, 26, 143-151.	1.0	70
8	Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines. Cancer Immunology Research, 2014, 2, 1090-1102.	1.6	62
9	A fully human IgG1 anti€PD€L1 MAb in an <i>in vitro</i> assay enhances antigen€specific T€cell responses. Clinical and Translational Immunology, 2016, 5, e83.	1.7	52
10	Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. Clinical Cancer Research, 2017, 23, 6833-6845.	3.2	51
11	Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. Journal of Circulating Biomarkers, 2016, 5, 5.	0.8	50
12	Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 93.e1-93.e11.	0.8	40
13	Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. Oncotarget, 2016, 7, 69014-69023.	0.8	38
14	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. Cancer Immunology Research, 2016, 4, 755-765.	1.6	36
15	The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. OncoImmunology, 2016, 5, e1188243.	2.1	26
16	Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack. , 2015, 3, 52.		22
17	An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients. Thrombosis and Haemostasis, 2011, 105, 931-932.	1.8	20
18	Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B). Medical Oncology, 2013, 30, 743.	1.2	20

#	Article	IF	Citations
19	Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 3055-3055.	0.8	19
20	Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patientsâ€"a pilot study. Supportive Care in Cancer, 2012, 20, 2713-2720.	1.0	7
21	Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses. , 2015, 3, P132.		4
22	Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression. , 2015, 3, P253.		0
23	Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells. , 2015, 3, P254.		0